TD Cowen analyst Phil Nadeau has maintained their bullish stance on VYGR stock, giving a Buy rating on November 1. Phil Nadeau’s rating ...
Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer's; on track to generate top-line data H1 2025 - - Recent third-party clinical data esta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback